Odyssey Therapeutics, Inc. (ODTX)
19.00
+0.88
(+4.86%)
USD |
NASDAQ |
Oct 09, 16:00
18.92
-0.08
(-0.42%)
After-Hours: 20:00
Odyssey Therapeutics Enterprise Value : 624.18M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 624.18M |
| October 08, 2026 | 582.04M |
| October 07, 2026 | 580.12M |
| October 06, 2026 | 582.52M |
| October 05, 2026 | 712.30M |
| October 02, 2026 | 706.80M |
| October 01, 2026 | 692.19M |
| September 30, 2026 | 778.39M |
| September 29, 2026 | 788.93M |
| September 28, 2026 | 742.48M |
| September 25, 2026 | 696.50M |
| September 24, 2026 | 668.72M |
| September 23, 2026 | 708.47M |
| September 22, 2026 | 832.03M |
| September 21, 2026 | 818.62M |
| September 18, 2026 | 881.84M |
| September 17, 2026 | 826.29M |
| September 16, 2026 | 821.50M |
| September 15, 2026 | 767.38M |
| September 14, 2026 | 876.09M |
| September 11, 2026 | 893.81M |
| September 10, 2026 | 846.40M |
| September 09, 2026 | 888.07M |
| September 08, 2026 | 1.006B |
| September 04, 2026 | 1.092B |
| Date | Value |
|---|---|
| September 03, 2026 | 978.58M |
| September 02, 2026 | 989.12M |
| September 01, 2026 | 887.59M |
| August 31, 2026 | 888.54M |
| August 28, 2026 | 880.88M |
| August 27, 2026 | 958.47M |
| August 26, 2026 | 941.23M |
| August 25, 2026 | 970.44M |
| August 24, 2026 | 918.72M |
| August 21, 2026 | 978.10M |
| August 20, 2026 | 895.73M |
| August 19, 2026 | 875.61M |
| August 18, 2026 | 765.46M |
| August 17, 2026 | 713.26M |
| August 14, 2026 | 707.04M |
| August 13, 2026 | 706.56M |
| August 12, 2026 | 747.74M |
| August 11, 2026 | 688.84M |
| August 10, 2026 | 776.00M |
| August 07, 2026 | 728.11M |
| August 06, 2026 | 746.31M |
| August 05, 2026 | 714.70M |
| August 04, 2026 | 670.16M |
| August 03, 2026 | 582.52M |
| July 31, 2026 | 620.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
| Vericel Corp. | 1.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.79M |
| Total Expenses (Quarterly) | 52.79M |
| EPS Diluted (Quarterly) | -1.102 |
| Earnings Yield | -18.72% |
| Normalized Earnings Yield | -18.52 |